Berenberg upgrades Eli Lilly stock rating on obesity drug strength

Berenberg upgraded Eli Lilly to Buy from Hold and raised its price target to $1,400 from $1,220, implying roughly 25% upside from the reported $1,138 share price. The firm cited Lilly's approximately 50% trailing-12-month revenue growth, obesity-drug leadership through Zepbound and Mounjaro, and potential upside to FY2026 guidance as demand benefits from the Medicare Bridge program and an expected Foundayo diabetes approval. Lilly has committed about $60 billion year-to-date across more than 25 business-development deals, including the approximately $2.875 billion Merida Biosciences acquisition, supporting pipeline diversification despite intensifying GLP-1 competition.

Analysis

LLY’s upside now depends less on incremental GLP-1 demand and more on whether it can defend premium economics as oral entrants broaden access. A successful oral diabetes launch would expand the treated population rather than merely cannibalize injectables, but the near-term earnings benefit will be constrained by gross-to-net discounts, launch spending and manufacturing ramp costs. The more durable read-through is that a lower-friction formulation could improve Lilly’s payer negotiations and reduce NVO’s ability to compete solely through price or international-market expansion.

The large business-development spend is potentially multiple-accretive only if it extends Lilly’s growth duration beyond the current incretin franchise; otherwise investors should treat it as an expensive attempt to offset eventual GLP-1 price erosion. The market is likely underpricing integration, clinical and capital-allocation risk from a deal pace of this scale, particularly with long-duration healthcare multiples vulnerable while Treasury yields remain elevated. Verify the FDA timing, product identity and label scope for the cited oral asset before underwriting any 2026 revenue contribution; a delay or a narrow label would quickly undermine the implied guidance upside.

NVO is the cleaner relative short because an oral Lilly diabetes product, if differentiated on efficacy or tolerability, pressures NVO’s diabetes funnel before its oral weight-loss strategy is fully established. That said, a broad obesity market can support both companies, so this is a share-shift trade rather than a directional wager against GLP-1 demand. Over 6-18 months, the key structural risk to both is payer utilization management: broader Medicare-linked access can raise volumes while simultaneously accelerating rebate pressure and lowering realized revenue per patient.

Key Decisions for Investors

• Initiate a 3-6 month long LLY / short NVO pair, sized beta-neutral, only after confirming the oral-product regulatory catalyst and label. Target 10-15% relative performance if Lilly validates a differentiated oral launch; exit if approval is delayed beyond H2 2026, if the label is not meaningfully differentiated, or if NVO closes the efficacy/access gap.
• For directional exposure, accumulate LLY on post-catalyst volatility rather than chase the analyst-target move; use a 12-month fundamental target near the cited $1,400 level, with risk limited by reducing exposure on a sustained break below $1,025 or on 2027 guidance that fails to show incremental oral-franchise contribution.
• Monitor quarterly net price, gross margin and obesity-drug supply commentary rather than prescription volume alone. A sequential deterioration in realized pricing despite volume growth would signal payer capture of the economics and warrants trimming both LLY and the broader GLP-1 complex.
• Do not establish a JPM position from this development. The relevant cross-asset watch item is the 10-year yield: a persistent move materially above 5% can compress LLY’s terminal-growth multiple even if operating results beat, favoring the relative LLY/NVO expression over an outright long.